- Home
- BXMX vs ARQT Comparison
BXMX vs ARQT Comparison
Compare BXMX & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXMX
- ARQT
- Stock Information
- Founded
- BXMX 2004
- ARQT 2016
- Country
- BXMX United States
- ARQT United States
- Employees
- BXMX N/A
- ARQT N/A
- Industry
- BXMX Investment Managers
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BXMX Finance
- ARQT Health Care
- Exchange
- BXMX Nasdaq
- ARQT Nasdaq
- Market Cap
- BXMX 1.5B
- ARQT 1.7B
- IPO Year
- BXMX N/A
- ARQT 2020
- Fundamental
- Price
- BXMX $13.51
- ARQT $13.04
- Analyst Decision
- BXMX
- ARQT Strong Buy
- Analyst Count
- BXMX 0
- ARQT 6
- Target Price
- BXMX N/A
- ARQT $18.80
- AVG Volume (30 Days)
- BXMX 205.6K
- ARQT 2.2M
- Earning Date
- BXMX 01-01-0001
- ARQT 05-06-2025
- Dividend Yield
- BXMX 7.24%
- ARQT N/A
- EPS Growth
- BXMX N/A
- ARQT N/A
- EPS
- BXMX N/A
- ARQT N/A
- Revenue
- BXMX N/A
- ARQT $212,819,000.00
- Revenue This Year
- BXMX N/A
- ARQT $61.15
- Revenue Next Year
- BXMX N/A
- ARQT $37.98
- P/E Ratio
- BXMX N/A
- ARQT N/A
- Revenue Growth
- BXMX N/A
- ARQT 100.03
- 52 Week Low
- BXMX $11.75
- ARQT $6.99
- 52 Week High
- BXMX $13.75
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- BXMX 58.48
- ARQT 40.51
- Support Level
- BXMX $13.41
- ARQT $13.27
- Resistance Level
- BXMX $13.55
- ARQT $14.30
- Average True Range (ATR)
- BXMX 0.10
- ARQT 0.71
- MACD
- BXMX -0.01
- ARQT -0.07
- Stochastic Oscillator
- BXMX 55.17
- ARQT 10.94
About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options strategy of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.